Adenosine A(2A) receptor antagonists as new agents for the treatment of Parkinson's disease

Trends in Pharmacological Sciences

Volumn 18, Issue 9, 1997, Pages 338-344

  Richardson, Peter J ^a   Kase, Hiroshi ^b   Jenner, Peter G ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3,7 DIMETHYL 1 PROPARGYLXANTHINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 AMINO 8 CHLORO 1 PHENYL 1,2,4 TRIAZOLO[4,3 A]QUINOXALINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 8 (4 FLUOROBENZYL) 2 (2 FURYL)PYRAZOLO[4,3 C][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 (3 CHLOROSTYRYL)CAFFEINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ACETYLCHOLINE; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; CAFFEINE; NEUROPEPTIDE; UNCLASSIFIED DRUG; ADENOSINE RECEPTOR; ANTIPARKINSON AGENT;

4 AMINOBUTYRIC ACID RELEASE; BRAIN CIRCULATION; CELL DEGENERATION; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; GENE EXPRESSION; HUMAN; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; NEOSTRIATUM; PATHOPHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; HUMANS; NEOSTRIATUM; PARKINSON DISEASE; RECEPTORS, PURINERGIC P1;

EID: 0030611334     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(97)01096-1     Document Type: Review

References (48)

1. Kopin, I. J. (1993) Annu. Rev. Pharmacol. Toxicol. 32, 467-495
2. Pearce, J. M. S. (1984) Br. Med. J. 288, 1777-1778
3. Walkinshaw, G. and Waters, C. M. (1995) J. Clin. Invest. 95, 2458-2464
4. Ben Shachar, D., Zuk, R. and Glinka, Y. (1995) J. Neurochem. 64, 718-723
5. Hagan, J. J., Middlemiss, D. N., Sharpe, P. C. and Poste, G. H. (1997) Trends Pharmacol. Sci. 18, 156-163
6. Gerfen, C. R. (1992) Trends Neurosci. 15, 133-139
7. Graybiel, A. M. (1990) Trends Neurosci. 13, 244-253
8. Kawaguchi, Y., Wilson, C. J., Augood, S. J. and Emson, P. C. (1995) Trends Neurosci. 18, 527-535
9. Gerfen, C. R. et al. (1990) Science 250, 1429-1432
10. Surmeier, D. J. et al. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10178-10182
11. Calabresi, P., Mercuri, N. B., Sancesario, G. and Bernardi, G. (1993) Brain 116, 433-452
12. Mitchell, I. J. et al. (1989) Neuroscience 32, 213-226
13. Augood, S. J. et al. (1989) Mol. Brain Res. 61, 85-92
14. Jolkkonen, J., Jenner, P. and Marsden, C. D. (1995) Mol. Brain Res. 32, 297-307
15. Fredholm, B. B. et al. (1994) Pharmacol. Rev. 46, 143-156
16. Martinez-Mir, M. I., Probst, A. and Palacious, J. M. (1991) Neuroscience 42, 697-703
17. Kirk, I. P. and Richardson, P. J. (1995) Br. J. Pharmacol. 114, 537-543
18. Daly, J. W., Butts-Lamb, P. and Padgett, W. (1983) Cell Mol. Neurobiol. 3, 69-80
19. Fink, J. S. et al. (1992) Mol. Brain Res. 14, 186-195
20. Schiffman, S. N., Jacobs, O. and Vanderhaegen, J. J. (1991) J. Neurochem. 57, 1062-1067
21. Dixon, A. K., Gubitz, A. K., Sirinathsinghji, D. J. S., Richardson, P. J. and Freeman, T. (1996) Br. J. Pharmacol. 118, 1461-1468
22. Nonaka, H. et al. (1994) Mol. Pharmacol. 46, 817-822
23. Shimada, J., Suzuki, F., Nonaka, H., Ishii, A. and Ichikawa, S. (1992) J. Med. Chem. 35, 2342-2345
24. Baraldi, P. G. et al. (1995) Curr. Med. Chem. 2, 707-722
25. Ongini, E. and Fredholm, B. B. (1996) Trends Pharmacol. Sci. 17, 364-372
26. Pollack, A. E. and Wooten, G. F. (1992) Mol. Brain Res. 13, 35-41
27. Schiffmann, S. N. and Vanderhaeghen, J. J. (1993) J. Neurosci. 13, 1080-1087
28. Kirk, I. P. and Richardson, P. J. (1994) J. Neurochem. 62, 960-966
29. Mori, A., Shindou, T., Ichimura, M., Nonaka, H. and Kase, H. (1996) J. Neurosci. 16, 605-611
30. Atkins, P. T., Surmeier, D. J. and Kitai, S. T. (1990) Nature 344, 240-242
31. Di Chiara, G., Morelli, M. and Consolo, S. (1994) Trends Neurosci. 17, 228-233
32. Kurokawa, M., Kirk, I. P., Kirkpatrick, K. A., Kase, H. and Richardson, P. J. (1994) Br. J. Pharmacol. 113, 43-48
33. Brown, S. J., James, S., Reddington, M. and Richardson, P. J. (1990) J. Neurochem. 55, 31-38
34. Gubitz, A. K., Widdowson, L., Kurokawa, M., Kirkpatrick, K. A. and Richardson, P. J. (1996) J. Neurochem. 67, 374-381
35. Kurokawa, M., Koga, K., Kase, H., Nakamura, J. and Kuwana, Y. (1996) J. Neurochem. 66, 1882-1888
36. Jin, S., Johansson, B. and Fredholm, B. B. (1993) J. Pharmacol. Exp. Ther. 267, 801-808
37. Vellucci, S. V., Sirinathsinghji, D. J. S. and Richardson, P. J. (1993) Psychopharmacology 111, 383-388
38. Ferre, S., von Euler, G., Johansson, B., Fredholm, B. B. and Fuxe, K. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7237-7241
39. Morelli, M., Fenu, S., Pinna, A. and Di Chiara, G. (1994) Eur. J. Pharmacol. 251, 21-25
40. Pinna, A., Di Chiara, G., Wardas, J. and Morelli, M. (1996) Eur. J. Neurosci. 8, 1176-1181
41. Ferre, S., O'Connor, W. T., Fuxe, K. and Ungerstedt, U. (1993) J. Neurosci. 13, 5402-5406
42. Mally, J. and Stone, T. W. (1994) J. Pharm. Pharmacol. 46, 515-517
43. Brown, S. J., Gill, R., Evenden, J. L., Iversen, S. D. and Richardson, P. J. (1991) Psychopharmacology 103, 78-82
44. Jiang, H. et al. (1993) Brain Res 613, 347-351
45. Barraco, R. A., Martens, K. A., Parizon, M. and Normile, H. J. (1993) Brain Res. Bull. 31, 397-404
46. Kanda, T., Shiozaki, S., Shimada, J., Suzuki, F. and Nakamura, J. (1994) Eur. J. Pharmacol. 256, 263-268
47. Lang, K. W., Loschmann, P. A., Wachtel, H. et al. (1992) Eur. J. Pharmacol. 212, 247-252
48. Dixon, A. K., Crawford, S. P. and Richardson, P. J. (1986) Drug Dev. Res. 37, 151